Home

news002

FDA Requests More Information on Certriad

LONDON (AP) - AstraZeneca PLC and Abbott Laboratories said that the U.S. Food and Drug Administration has asked for more information about their Certriad cholesterol drug before approving it for sale.

The companies said that FDA has sought more data in a so-called complete response letter (CRL) to their new drug application, which combines their cholesterol pills TriLipix and Crestor.

Abbott's TriLipix is part of a class of drugs called fibrates that raise "good" HDL cholesterol while reducing triglycerides and "bad" LDL cholesterol. AstraZeneca's Crestor is a statin drug that lowers bad cholesterol while raising good cholesterol.

Studies conducted by the companies compared the combination pill versus separate treatment with statin and fibrate drugs.

The companies' application to the FDA seeks approval to treat dyslipidemia, a disorder characterized by elevated cholesterol and triglycerides, a type of fat found in the blood stream. More than 100 million adults in the U.S. have the disorder, according to the American Heart Association.

The companies said they will continue discussions with the FDA to "determine the next steps," while responding to the request for more information.

Source: Associated Press

News & Events

  • T Cell Proliferation Assays ProImmune Ltd, a leader in epitope discovery, immunogenicity, an... Read more>>
  • GSK Receives EMEA Approval for Duodart LONDON (AP) - Pharmaceutical company GlaxoSmithKline... Read more>>
  • Novozymes Partnering With ProMetic Life Sciences Inc.Drug Discovery & Development - April 0... Read more>>
  • FDA Requests More Information on Certriad LONDON (AP) - AstraZeneca PLC and Abbott Laborator... Read more>>
  • Food and Drug Administration NOTICES Meetings:   Internationa... Read more>>
  • AllTranz Developing Multi-Use Transdermal Patch   AllTranz, Lexington, Ky., is focused on t... Read more>>
  • New Class of Brain-Protecting Drugs Emerging Researchers have identified a compound that mim... Read more>>
  • Statins May Slow Progression Of Multiple Sclerosis, New Study Finds A UCSF-led study exa... Read more>>
  • Pending Litigation to Delay Launch of Generic Asacol Boehringer Ingelheim’s Roxane Laboratori... Read more>>
  • Proximagen Signs Deal With Upsher-Smith Proximagen Neuroscience plc, a biotechnology company... Read more>>
  • U.S. Food & Drug Administration (FDA) New and Generic Drug Approvals Calan (verapamil h... Read more>>
  • in vivo Pharmacodynamic Assay Trevigen offers a validated assay with higher sensitivity and... Read more>>